Synlogic SYBX announced that it has initiated the phase I study of SYNB1934, an investigational synthetic biotic candidate for the treatment of phenylketonuria (“PKU”). The candidate will be ...
网页链接Synlogic SYBX announced that it has initiated the phase I study of SYNB1934, an investigational synthetic biotic candidate for the treatment of phenylketonuria (“PKU”). The candidate will be ...
网页链接
精彩评论